• Applied Workflows with EZ Cap™ Human PTEN mRNA (ψUTP): Proto

  2026-06-10

  EZ Cap™ Human PTEN mRNA (ψUTP) unlocks robust PTEN restoration and pathway inhibition in advanced cancer models, thanks to its engineered Cap 1 structure and pseudouridine modification. This guide translates cutting-edge reference study findings and expert workflow insights into actionable, high-fidelity protocols for translational and functional rescue research.

• Hexose Diphosphate in Energy Homeostasis and Inflammation Mo

  2026-06-09

  Hexose diphosphate empowers precise dissection of metabolic flux and inflammatory pathways in cardiovascular and aging research. This guide details robust workflows, troubleshooting, and protocol enhancements for leveraging this water-soluble, metabolically active compound in both standard and advanced cellular assays.

• Omeprazole (A2845): Technical Guide for Gastric Acid Models

  2026-06-09

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor optimized for in vitro and preclinical research on gastric acid secretion mechanisms and antiulcer activity. It should not be used for diagnostic or clinical applications. Precise handling and protocol adherence are essential to ensure reproducible results in gastric acid-related disorder studies.

• HyperPFU™ high-fidelity DNA polymerase: Technical Use Guidan

  2026-06-08

  HyperPFU™ high-fidelity DNA polymerase addresses the challenge of amplifying long, GC-rich, or otherwise difficult DNA templates that standard enzymes struggle with due to low fidelity or processivity. This enzyme is optimal for workflows demanding high accuracy and blunt-ended PCR products, but is not suitable for protocols requiring 3'-A overhangs or sticky-end ligation.

• BCL-XL and MCL-1 Inhibition Sensitizes Glioblastoma to Apopt

  2026-06-08

  Koessinger et al. demonstrate that glioblastoma displays heightened expression of anti-apoptotic BCL-XL and MCL-1, rendering these tumors highly sensitive to BH3-mimetic inhibitors. Their work reveals a critical vulnerability in glioblastoma stem-like cells and provides a rationale for targeting BCL-2 family proteins to overcome therapeutic resistance.

• Tomivosertib Reversibly Suppresses Human DRG Neuron Hyperact

  2026-06-07

  This study demonstrates that Tomivosertib, a selective MNK1/2 inhibitor, rapidly and reversibly suppresses spontaneous activity in human dorsal root ganglion neurons derived from patients with radiculopathy. The findings provide direct evidence linking MNK-eIF4E signaling to neuronal hyperexcitability in neuropathic pain, highlighting a new translational target for pain research.

• Scenario-Driven Lab Solutions with MCL-1 Inhibitor A-1210477

  2026-06-06

  Discover how 'MCL-1 inhibitor A-1210477' (SKU B6011) offers reproducible, data-backed answers to common challenges in apoptosis assays and cancer cell survival research. This scenario-driven guide distills evidence and expert workflow advice for reliable protocol development and product selection.

• Myriocin Restores Metabolic Balance via AMPK-PGC1α in dAGE M

  2026-06-05

  This study demonstrates that Myriocin, a serine palmitoyltransferase inhibitor, reverses diet-induced metabolic syndrome in mice by activating AMPK-PGC1α signaling, promoting mitochondrial biogenesis and adipose tissue browning. The findings reveal sphingolipid inhibition as a promising approach for obesity and metabolic disorder research.

• Meropenem Trihydrate in Resistance & Infection Research Work

  2026-06-05

  Meropenem trihydrate stands at the forefront of antibiotic resistance research, enabling rapid phenotyping and translational modeling of gram-negative and gram-positive infections. This guide delivers expert workflows, troubleshooting, and data-driven insights that maximize reproducibility and reveal new diagnostic possibilities.

• Dimetridazole Enhances Cefotaxime Against MDR E. coli via Me

  2026-06-04

  The referenced study demonstrates that dimetridazole significantly potentiates cefotaxime’s activity against multidrug-resistant E. coli by disrupting membrane integrity and altering fatty acid biosynthesis. These findings provide a mechanistic basis for repurposing dimetridazole as a synergistic adjunct in combating antimicrobial resistance.

• Okadaic Acid (A4540): Technical Guide for PP1 Inhibition

  2026-06-04

  Okadaic acid is a nanomolar-potency inhibitor of protein phosphatase 1 (PP1) and PP2A, allowing researchers to precisely dissect phosphorylation-dependent signaling, cell apoptosis induction, and related pathways. It is best suited for controlled biochemical and cell biology experiments, but should be avoided in studies where broad-spectrum phosphatase inhibition or off-target effects could confound results.

• 7ACC2: Monocarboxylate Transporter 1 Inhibitor for Cancer Me

  2026-06-03

  7ACC2 stands out as a nanomolar-potency monocarboxylate transporter 1 inhibitor with dual action against lactate uptake and mitochondrial pyruvate transport, enabling precise dissection of cancer cell metabolic vulnerabilities. Its robust performance in radiosensitization and tumor growth delay makes it a pivotal asset for translational metabolism research.

• Talabostat Mesylate: Enabling Immune Modulation in Tumor Res

  2026-06-03

  This thought-leadership article explores Talabostat mesylate's mechanistic role as a DPP4 and FAP inhibitor, bridging fundamental enzymology with translational oncology strategy. Integrating insights from recent inflammasome research and practical workflow advances, it offers actionable guidance for experimentalists seeking to harness tumor microenvironment modulation and immune activation in cancer models. The discussion distinguishes itself by tying mechanistic underpinnings to protocol design, competitive context, and future translational impact.

• SARS-CoV-2 N Protein Disrupts GADD34-Driven Antiviral Defens

  2026-06-02

  Liu et al. (2024) revealed a novel mechanism by which the SARS-CoV-2 nucleocapsid (N) protein subverts innate immunity. By sequestering GADD34 mRNA into atypical foci, the N protein impairs IRF3 activation and type I interferon signaling, advancing our understanding of viral immune evasion and providing a basis for future antiviral research.

• P/Q-Type Channel Blockade Reduces Ischemic Brain Injury in R

  2026-06-02

  The reference study demonstrates that targeting ω-agatoxin IVA-sensitive calcium channels with α-eudesmol reduces excitotoxic glutamate release and limits brain injury after focal ischemia in rats. These findings highlight the mechanistic link between P/Q-type channel inhibition and neuroprotection, offering a translational framework for future synaptic transmission and neuroprotection research.

8290 records 10/553 page Previous Next First page 上5页 678910 下5页 Last page